Comprehensive Menopause Society
Certified Practitioner [MSCP] Exam
Preparation: 200 Practice Questions
with Evidence-Based Rationales
latest 2026~Graded A+ /Instant
Download PDF
1. Average Age of Menopause
• Question: What is the average age of natural menopause in
women in the United States?
• Correct Answer: 51 years.
• Rationale: The average age of natural menopause in the U.S. is
approximately 51 years, with 95% of women experiencing it
between ages 45 and 55. This is a key demographic fact in
menopause physiology.
2. Menopause Staging System
• Question: What is the STRAW+10 staging system primarily used
for?
• Correct Answer: Standardizing menopause transition stages.
• Rationale: The STRAW+10 system provides a standardized
framework for describing the stages of reproductive aging,
including the menopausal transition, based on menstrual cycle
characteristics and hormonal changes.
3. Primary Ovarian Insufficiency (POI) Age
, • Question: What is the definition of primary ovarian insufficiency
(POI)?
• Correct Answer: Loss of ovarian function before age 40.
• Rationale: POI is characterized by amenorrhea, low estrogen, and
elevated FSH before age 40. This is distinguished from early
menopause, which occurs between ages 40-45.
4. Hormone Therapy for POI
• Question: In women with primary ovarian insufficiency, until
approximately what age is hormone therapy recommended?
• Correct Answer: The average age of natural menopause (~51).
• Rationale: Hormone therapy is recommended for women with POI
until the average age of natural menopause to mitigate the long-
term health risks associated with early estrogen deficiency, such as
osteoporosis and cardiovascular disease.
5. Most Effective VMS Treatment
• Question: What is the most effective treatment for moderate to
severe vasomotor symptoms such as hot flashes and night sweats?
• Correct Answer: Systemic hormone therapy.
• Rationale: Systemic estrogen-containing hormone therapy is the
most effective treatment for vasomotor symptoms, reducing
frequency and severity by up to 75-80%.
6. Non-Hormonal VMS Treatment
• Question: Which non-hormonal medication was FDA-approved
specifically for moderate to severe hot flashes?
• Correct Answer: Fezolinetant.
• Rationale: Fezolinetant is a neurokinin 3 receptor antagonist that
works by blocking the neurokinin B pathway in the hypothalamus,
which is a key driver of hot flashes. It is approved for non-
hormonal treatment of vasomotor symptoms.
,7. Duration of Vasomotor Symptoms
• Question: How long do vasomotor symptoms typically persist on
average?
• Correct Answer: 7-10 years or longer.
• Rationale: Vasomotor symptoms can last for many years, with an
average duration of 7.4 years. This highlights the importance of
appropriate and individualized management strategies.
8. Hormone Therapy and Endometrial Protection
• Question: Which hormone therapy regimen is recommended for a
woman with an intact uterus experiencing menopausal symptoms?
• Correct Answer: Estrogen plus progestogen.
• Rationale: In women with an intact uterus, estrogen plus
progestogen is required to protect the endometrium from
hyperplasia and reduce the risk of endometrial cancer associated
with unopposed estrogen.
9. VTE Risk and Route of Administration
• Question: Which route of estrogen administration in hormone
therapy is associated with a lower risk of venous thromboembolism
compared to oral?
• Correct Answer: Transdermal.
• Rationale: Transdermal estradiol bypasses first-pass hepatic
metabolism, resulting in lower thrombotic risk than oral
formulations.
10. Hormone Therapy Contraindication
• Question: What is a key contraindication for systemic menopausal
hormone therapy?
• Correct Answer: History of estrogen-sensitive breast cancer.
, • Rationale: A personal history of estrogen-sensitive breast cancer is
a contraindication due to the potential increased risk of recurrence
with systemic estrogen.
11. Breast Cancer Risk and EPT
• Question: What is the impact of combined estrogen-progestin
therapy on breast cancer risk in long-term use?
• Correct Answer: May slightly increase risk.
• Rationale: Combined therapy is associated with a small increased
breast cancer risk, particularly with longer duration, unlike
estrogen-alone therapy in hysterectomized women.
12. FDA-Approved Indication for Hormone Therapy
• Question: Which is an FDA-approved indication for hormone
therapy besides vasomotor symptoms?
• Correct Answer: Prevention of osteoporosis.
• Rationale: Hormone therapy is approved by the FDA for the
prevention of postmenopausal osteoporosis.
13. Hormone Therapy Duration
• Question: What is the recommended approach for hormone
therapy duration in symptomatic women?
• Correct Answer: Individualized, using the lowest effective dose for
the shortest time needed.
• Rationale: The duration of hormone therapy should be based on
individual symptom severity, benefits, risks, and patient
preferences with annual reassessment.
14. Initial Treatment for GSM
• Question: For genitourinary syndrome of menopause (GSM), what
is the preferred initial treatment for vaginal symptoms?
• Correct Answer: Low-dose local vaginal estrogen.
Certified Practitioner [MSCP] Exam
Preparation: 200 Practice Questions
with Evidence-Based Rationales
latest 2026~Graded A+ /Instant
Download PDF
1. Average Age of Menopause
• Question: What is the average age of natural menopause in
women in the United States?
• Correct Answer: 51 years.
• Rationale: The average age of natural menopause in the U.S. is
approximately 51 years, with 95% of women experiencing it
between ages 45 and 55. This is a key demographic fact in
menopause physiology.
2. Menopause Staging System
• Question: What is the STRAW+10 staging system primarily used
for?
• Correct Answer: Standardizing menopause transition stages.
• Rationale: The STRAW+10 system provides a standardized
framework for describing the stages of reproductive aging,
including the menopausal transition, based on menstrual cycle
characteristics and hormonal changes.
3. Primary Ovarian Insufficiency (POI) Age
, • Question: What is the definition of primary ovarian insufficiency
(POI)?
• Correct Answer: Loss of ovarian function before age 40.
• Rationale: POI is characterized by amenorrhea, low estrogen, and
elevated FSH before age 40. This is distinguished from early
menopause, which occurs between ages 40-45.
4. Hormone Therapy for POI
• Question: In women with primary ovarian insufficiency, until
approximately what age is hormone therapy recommended?
• Correct Answer: The average age of natural menopause (~51).
• Rationale: Hormone therapy is recommended for women with POI
until the average age of natural menopause to mitigate the long-
term health risks associated with early estrogen deficiency, such as
osteoporosis and cardiovascular disease.
5. Most Effective VMS Treatment
• Question: What is the most effective treatment for moderate to
severe vasomotor symptoms such as hot flashes and night sweats?
• Correct Answer: Systemic hormone therapy.
• Rationale: Systemic estrogen-containing hormone therapy is the
most effective treatment for vasomotor symptoms, reducing
frequency and severity by up to 75-80%.
6. Non-Hormonal VMS Treatment
• Question: Which non-hormonal medication was FDA-approved
specifically for moderate to severe hot flashes?
• Correct Answer: Fezolinetant.
• Rationale: Fezolinetant is a neurokinin 3 receptor antagonist that
works by blocking the neurokinin B pathway in the hypothalamus,
which is a key driver of hot flashes. It is approved for non-
hormonal treatment of vasomotor symptoms.
,7. Duration of Vasomotor Symptoms
• Question: How long do vasomotor symptoms typically persist on
average?
• Correct Answer: 7-10 years or longer.
• Rationale: Vasomotor symptoms can last for many years, with an
average duration of 7.4 years. This highlights the importance of
appropriate and individualized management strategies.
8. Hormone Therapy and Endometrial Protection
• Question: Which hormone therapy regimen is recommended for a
woman with an intact uterus experiencing menopausal symptoms?
• Correct Answer: Estrogen plus progestogen.
• Rationale: In women with an intact uterus, estrogen plus
progestogen is required to protect the endometrium from
hyperplasia and reduce the risk of endometrial cancer associated
with unopposed estrogen.
9. VTE Risk and Route of Administration
• Question: Which route of estrogen administration in hormone
therapy is associated with a lower risk of venous thromboembolism
compared to oral?
• Correct Answer: Transdermal.
• Rationale: Transdermal estradiol bypasses first-pass hepatic
metabolism, resulting in lower thrombotic risk than oral
formulations.
10. Hormone Therapy Contraindication
• Question: What is a key contraindication for systemic menopausal
hormone therapy?
• Correct Answer: History of estrogen-sensitive breast cancer.
, • Rationale: A personal history of estrogen-sensitive breast cancer is
a contraindication due to the potential increased risk of recurrence
with systemic estrogen.
11. Breast Cancer Risk and EPT
• Question: What is the impact of combined estrogen-progestin
therapy on breast cancer risk in long-term use?
• Correct Answer: May slightly increase risk.
• Rationale: Combined therapy is associated with a small increased
breast cancer risk, particularly with longer duration, unlike
estrogen-alone therapy in hysterectomized women.
12. FDA-Approved Indication for Hormone Therapy
• Question: Which is an FDA-approved indication for hormone
therapy besides vasomotor symptoms?
• Correct Answer: Prevention of osteoporosis.
• Rationale: Hormone therapy is approved by the FDA for the
prevention of postmenopausal osteoporosis.
13. Hormone Therapy Duration
• Question: What is the recommended approach for hormone
therapy duration in symptomatic women?
• Correct Answer: Individualized, using the lowest effective dose for
the shortest time needed.
• Rationale: The duration of hormone therapy should be based on
individual symptom severity, benefits, risks, and patient
preferences with annual reassessment.
14. Initial Treatment for GSM
• Question: For genitourinary syndrome of menopause (GSM), what
is the preferred initial treatment for vaginal symptoms?
• Correct Answer: Low-dose local vaginal estrogen.
